Physician

Ketan D. Doshi, M.D.

According to 2025 Medicare claims, Ketan Doshi, M.D. (NPI: 1750573069) practices hematology/oncology in the Ocala, FL market, with the plurality of this provider's patient population coming from Marion, FL. This provider's primary affiliated billing organization is OCALA ONCOLOGY CENTER PL (NPI: 1356300958; TIN: 900336929) and primary practice location at 34474-4445. Doshi is affiliated with the Primary Care Alliance, LLC (ACO ID: D0010), participating under the REACH model.

Doshi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 928 traditional Medicare patients, billed 172,087 HCPCS/CPT codes, and received $2,341,341 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,536 prescription claims across 287 beneficiaries totaling $4,514,185 in drug costs, led by Lenalidomide (Lenalidomide). 2021 DME data shows 11 claims. Open Payments data shows 228 records totaling $456,047. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $997,378 to $4,514,185. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,212 to $465.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	900	250,213	$2,859,698
2016	1,075	237,435	$3,156,242
2017	1,115	294,128	$3,908,479
2018	1,044	309,954	$3,981,239
2019	1,132	445,123	$5,384,573
2020	968	306,178	$3,910,469
2021	886	309,605	$3,375,321
2022	889	250,398	$3,155,689
2023	901	204,067	$3,200,402
2024	928	172,087	$2,341,341

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	167	979	$997,378
2016	221	1,047	$1,027,187
2017	230	1,174	$1,561,296
2018	250	1,208	$2,272,312
2019	271	1,374	$2,493,533
2020	252	1,407	$4,072,721
2021	263	1,283	$3,695,123
2022	237	1,271	$3,942,511
2023	252	1,318	$3,450,041
2024	287	1,536	$4,514,185

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	130	$40,561
2016	12	146	$48,411
2017	N/R	56	$20,063
2018	N/R	37	$6,061
2019	N/R	14	$803
2020	N/R	23	$811
2021	N/R	11	$706
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	310	453	$70
80053	Blood test, comprehensive group of blood chemicals	536	1,777	$10
36415	Insertion of needle into vein for collection of blood sample	537	2,477	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	526	2,588	$8
83615	Lactate dehydrogenase (enzyme) level	490	1,503	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	54	1,324	$608,033
Imbruvica	Ibrutinib	24	672	$367,380
Xtandi	Enzalutamide	26	780	$361,257
Kisqali	Ribociclib Succinate	19	532	$296,915
Venclexta	Venetoclax	16	480	$243,543

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	197	$15,123	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	31	$440,924	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ketan D. Doshi, M.D.?

Tedicare shows public-source Medicare data for Ketan D. Doshi, M.D. (NPI 1750573069), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ketan D. Doshi, M.D. have ACO affiliation data?

Ketan D. Doshi, M.D. is shown with ACO affiliation data for Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Ketan D. Doshi, M.D.?

Ketan D. Doshi, M.D. is linked to OCALA ONCOLOGY CENTER PL (billing NPI 1356300958) in the available physician profile data.

Does Ketan D. Doshi, M.D. have Open Payments data?

Ketan D. Doshi, M.D. has 228 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.